Corton Capital Inc. Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Corton Capital Inc. purchased a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 33,346 shares of the biopharmaceutical company's stock, valued at approximately $314,000. Corton Capital Inc. owned about 0.07% of Theravance Biopharma at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 20.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after purchasing an additional 95,304 shares during the period. Trexquant Investment LP increased its position in shares of Theravance Biopharma by 50.7% during the fourth quarter. Trexquant Investment LP now owns 151,083 shares of the biopharmaceutical company's stock valued at $1,422,000 after purchasing an additional 50,826 shares during the period. Barclays PLC grew its position in Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock valued at $529,000 after acquiring an additional 48,316 shares during the period. Magnetar Financial LLC grew its position in Theravance Biopharma by 125.8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 15,328 shares during the period. Finally, Townsquare Capital LLC bought a new stake in Theravance Biopharma in the fourth quarter valued at $136,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $11.33.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company's stock.

Theravance Biopharma Stock Performance

NASDAQ TBPH traded down $0.07 during trading hours on Monday, hitting $8.91. 123,577 shares of the company traded hands, compared to its average volume of 271,640. The business's 50-day moving average is $9.23 and its 200-day moving average is $9.30. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.90. The stock has a market capitalization of $445.46 million, a price-to-earnings ratio of -8.76 and a beta of -0.10.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.